ストックスクリーナーアプリを入手
7.40
2.49%
0.18
アフターアワーズ：
7.32
-0.08
-1.08%
前日終値:
$7.22
開ける：
$7.26
24時間の取引高:
57,833
Relative Volume:
0.27
時価総額：
$455.12M
収益：
-
当期純損益:
$-38.61M
株価収益率:
-7.4619
EPS:
-0.9917
ネットキャッシュフロー:
$-29.20M
1週間 パフォーマンス:
+7.56%
1か月 パフォーマンス:
+0.54%
6か月 パフォーマンス:
+25.21%
1年 パフォーマンス:
+121.23%
1日の値動き範囲:
$7.23
$7.555
1週間の範囲:
$6.785
$7.57
52週間の値動き範囲:
$3.17
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Compare EPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
7.40 | 444.05M | 0 | -38.61M | -29.20M | -0.9917 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-23 | 開始されました | William Blair | Outperform |
| 2025-07-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2025-06-16 | 開始されました | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | 開始されました | Craig Hallum | Buy |
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
すべてを表示
Eupraxia Pharmaceuticals Inc (EPRX) 最新ニュース
Eupraxia Pharmaceuticals to Highlight Drug-Delivery Pipeline at April Investor Conferences - TipRanks
Eupraxia (EPRX) to showcase Diffusphere pipeline at April investor events - Stock Titan
Eupraxia Pharmaceuticals (EPRX) schedules June 18, 2026 annual meeting - Stock Titan
EPRX Price Today: Eupraxia Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - mexc.co
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences - Investing News Network
New Highs: Can VLYPP weather a recessionTrade Performance Summary & AI Driven Price Forecasts - baoquankhu1.vn
Top iBio (IBIO) Competitors 2026 - MarketBeat
Whats the beta of Eupraxia Pharmaceuticals Inc stock2026 Top Gainers & Technical Pattern Recognition Alerts - baoquankhu1.vn
Institution Moves: What are Eupraxia Pharmaceuticals Incs recent SEC filings showing2026 EndofYear Setup & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
EPRX SEC FilingsEupraxia Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
New strong sell stocks for April 2nd - MSN
New Strong Sell Stocks for April 2nd - Yahoo Finance
ETFs Investing in Eupraxia Pharmaceuticals, Inc. Stocks - TradingView
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 26.3% in March - MarketBeat
Eupraxia Pharmaceuticals Projected to Post Earnings on Tuesday - National Today
Eupraxia Pharmaceuticals boasts $900 million peak sales potential: Analyst - MSN
Risk Recap: What is Eupraxia Pharmaceuticals Incs valuation compared to sectorVolume Spike & Daily Chart Pattern Signals - baoquankhu1.vn
Aug Chart Watch: Whats the beta of Eupraxia Pharmaceuticals Inc stockMarket Movers & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Eupraxia Pharmaceuticals (EPRX) to Release Earnings on Tuesday - MarketBeat
EPRX Stock On Retail Radar After Strong Remission Data In Digestive Disease Trial - Dailyhunt
Eupraxia Pharmaceuticals: Analyst Expects $900M In Peak SalesEupraxia Pharmaceuticals (NASDAQ:EPRX) - Benzinga
William Blair Initiates Coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) - MarketBeat
Eupraxia Pharmaceuticals Inc.: Fundamental Analysis and Financial Ratings | X43 | CA29842P1053 - marketscreener.com
If You Invested $1,000 in Eupraxia Pharmac (EPRX) - Stock Titan
Eupraxia Pharmaceuticals (EPRX) Receives a Rating Update from a Top Analyst - The Globe and Mail
You need to know this Canadian biotech stock, analyst says - Cantech Letter
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Earnings Results, Misses Estimates By $0.21 EPS - MarketBeat
Lifesci Capital Has Negative Outlook of EPRX FY2026 Earnings - MarketBeat
What is HC Wainwright's Estimate for EPRX Q1 Earnings? - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Lowered by Zacks Research - MarketBeat
Profit Recap: Will Eupraxia Pharmaceuticals Inc stock hit new highs in YEAR2026 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Q2 Earnings Estimate for EPRX Issued By HC Wainwright - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Given New $11.00 Price Target at HC Wainwright - Defense World
EPRX stock on retail radar after strong remission data in digestive disease trial - MSN
Buyout Rumor: Whats BioXcel Therapeutics Incs historical return2026 Trade Ideas & High Accuracy Swing Entry Alerts - baoquankhu1.vn
H.C. Wainwright cuts Eupraxia Pharmaceuticals price target on higher costs By Investing.com - Investing.com India
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis - Investing News Network
Eupraxia Pharmaceuticals Stock Surges on Drug Trial Win - TipRanks
A Little-Known Biotech Is Gaining Retail Buzz With Its Latest Trial Data - Stocktwits
H.C. Wainwright cuts Eupraxia Pharmaceuticals price target on higher costs - Investing.com
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
HC Wainwright Has Lowered Expectations for Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price - MarketBeat
Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI as RESOLVE Trial Advances - tipranks.com
Eupraxia (EPRX) shows strong symptom gains, clean safety in RESOLVE EoE trial - Stock Titan
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data - GlobeNewswire
Freedman lifts Eupraxia (EPRX) stake to 9% after 2026 share purchases - Stock Titan
Eupraxia Pharmaceuticals Inc (EPRX) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):